MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX:NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system, will host a research and development day featuring leading medical experts presenting on schizophrenia, treatment resistant schizophrenia and Rett syndrome on Wednesday, October 31, 2018 in New York City.
This invitation only event will be held at Convene, 730 Third Avenue, New York City, from 10:00 AM to 1:00 PM EDT. Institutional investors, analysts and media representatives interested in attending can email email@example.com to register and to receive additional details. Please note that pre-registration is required to attend in person.
John Kane, MD, Professor and Chairman of the Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell will present the topic, “Spectrum of Treatment Resistant Schizophrenia: New Therapeutic Mechanisms.” One of the leading researchers in the field of schizophrenia, Dr. Kane is a recipient of the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists.
Daniel Glaze, MD, Neurologist and Professor at Baylor College of Medicine in Houston, Texas, will address the topic, “Rett Syndrome: Natural History of Awake Breathing Dysfunction and Emerging Data.” Dr. Glaze's research has focused on Rett syndrome and includes investigations in the Rett Natural History Study, a multi-year study representing the largest group of Rett participants assessed repeatedly by direct examination.
“We are honored to have distinguished medical researchers in the field of schizophrenia and Rett syndrome, such as Dr. Kane and Dr. Glaze, join our discussions in New York,” said Stefan Weber, CEO of Newron. “We look forward to updating both the research community and investors with our progress on October 31.”
Newron’s senior executive management team will be presenting its financial outlook as well as updates on the company’s clinical and commercial pipeline, including its pivotal Phase III STARS study for Rett syndrome, two potentially pivotal studies for Evenamide for schizophrenia and treatment-resistant schizophrenia, and updates on Xadago®, the first New Chemical Entity approved in Europe and the U.S. for Parkinson's Disease in a decade.
Newron’s 2018 R&D Day will also be accessible via live webcast beginning 10:00 AM EDT (2:00 PM GMT, 3:00 PM CET). A link to the webcast will be available in the 2018 R&D Day section of the Company's website at https://www.newron.com/home/newron-rd-day.
About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system. The company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com.
This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements, and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange, where the shares of Newron are listed. This announcement is not an offer for sale of securities in the United States, Canada, Australia or Japan or any other jurisdiction where such an offer or solicitation would otherwise be unlawful. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Newron does not intend to register any of its securities in the United States or to conduct a public offering of its securities in the United States. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of this document shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.